Whitepaper · April 2, 2025
What the Medical Device Industry Can Learn From Past Cybersecurity Vulnerability Disclosures 2025
Ten Years of Data-Driven Insights on Medical Device Vulnerabilities, Disclosure Maturity, and FDA Enforcement
Executive summary
What this whitepaper covers
Since the FDA’s 2016 Postmarket Cybersecurity Guidance, the rate of ICS-CERT medical device advisories has grown 386%, signaling stronger transparency but also persistent cybersecurity weaknesses.
This 2025 update expands Medcrypt’s decade-long analysis of 2013–2024 ICS-CERT medical device advisories, revealing that while industry maturity has improved, vulnerability trends remain remarkably consistent.
Key findings:
- 59.8% of all vulnerabilities still stem from user authentication and code defects.
- Patch references decreased by 22% in 2024, despite new FDA Section 524B enforcement.
- Only 27 of the top 40 manufacturers maintain public vulnerability disclosure programs.
- Nearly half of all vulnerabilities (200/433) originated from just four vendors (Baxter, BD, Medtronic, Philips).
These data reveal that cybersecurity progress has plateaued — and that proactive risk management, not reactive disclosure, must define the next era of medical device security.
Why it matters
The regulatory and product context
Even after eight years of formal postmarket expectations, many manufacturers continue to treat vulnerability management as reactive.
The FDA’s Section 524B now mandates timely updates and patching, but patch reference rates fell sharply in 2024.
This suggests that while manufacturers are more transparent, they remain resource-limited, compliance-driven, and dependent on legacy processes.
For regulators, manufacturers, and healthcare delivery organizations alike, these findings underscore an urgent need for:
- Proactive, lifecycle-integrated security design rather than patch-based defense.
- Collaborative vulnerability disclosure processes across vendors, researchers, and CISA.
- Evidence-based security decisions rooted in longitudinal vulnerability data.
Key insights
What you’ll take away
- ICS-CERT advisories have increased 386% since FDA’s 2016 guidance — but vulnerability causes remain the same.
- Patch references dropped 22% year-over-year, despite legal obligations under 524B.
- Researchers are key contributors, now referenced in 68% of advisories.
- Disclosure transparency ≠ remediation; true maturity requires design-stage prevention and continuous monitoring.
- The industry must shift from compliance reporting to proactive risk reduction anchored in real-time intelligence.
Who should read this
- Medical Device Manufacturers (MDMs): Product security and engineering leaders managing FDA and global compliance.
- Regulatory and Quality Professionals: Teams responsible for postmarket surveillance and 524B compliance evidence.
- Healthcare Delivery Organizations (HDOs): Security and IT staff managing device vulnerabilities and risk.
- Policy and Standards Bodies: Agencies and working groups (FDA, CISA, MDIC, AAMI, IEC) shaping next-generation disclosure policy.
